LYEL vs DSC Comparison

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

DSC Holdings Ltd is an AI application infrastructure for China's used car industry. According to CIC, the Company has held over 90% market share in operating systems for China's used car dealers, giving it nationwide dealer connections and massive, granular, proprietary, real-time industry data. Building on this digital foundation, the group further supports used car dealers with essential transaction services across their workflows. Its Services engage and benefit thousands of dealer collaborators, such as inspectors, transporters, and other internet platforms, creating an ecosystem with used car dealers at its center.